The purpose of the study is to see if ninerafaxstat can improve health status in people with symptomatic non-obstructive hypertrophic cardiomyopathy. The study will look at how the medication affects symptoms and quality of life, as well as how well people can exercise. The treatment will be given over a period of 12 weeks, with the highest daily dose being 400 milligrams and a total maximum dose of 33,600 milligrams over the entire treatment period.

During the study, participants will undergo various assessments including heart ultrasound examinations, which use sound waves to create pictures of the heart, and exercise tests where breathing and heart function are measured while exercising. The study will track changes in symptoms and how they affect daily activities by using questionnaires that ask about physical limitations, symptoms, quality of life, and overall health. Neither the participants nor the doctors will know who is receiving the actual medication and who is receiving the placebo during the study.

The purpose of the study is to find out whether low dose hydrochlorothiazide causes less of an increase in the pressure difference across the blocked area of the heart compared to valsartan in patients who have both the obstructive heart condition and high blood pressure. Both medications are commonly used to treat high blood pressure, but doctors want to understand which one is better for patients with this specific heart condition. The study will measure the pressure gradient, which is the difference in pressure that occurs when blood tries to flow through the narrowed area of the heart.

This is a crossover study, which means that participants will receive both treatments at different times. The study is double-blind, meaning neither the participants nor the doctors will know which medication is being given at any particular time. Each treatment period will last for 30 days. During the study, measurements will be taken to see how each medication affects the blockage in the heart, blood pressure, heart function markers in the blood, and quality of life. Participants will need to be taking a medication called a betablocker at the highest dose they can tolerate before joining the study.

The study will evaluate how well direct oral anticoagulants work in preventing serious events like stroke, myocardial infarction (heart attack), and systemic embolism (blood clots traveling to other parts of the body) in people with Hypertrophic Cardiomyopathy who have reduced heart chamber function. Participants will be monitored through various tests, including ECG (electrocardiogram) and Holter monitoring (a portable device that records heart rhythm).

Participants in the study will be randomly assigned to receive either Sotagliflozin or a placebo, which looks like the medication but does not contain the active ingredient. The study will last for about 26 weeks, during which participants will take the medication and have regular check-ups to monitor their health and any changes in their symptoms. The study aims to understand how the medication affects the symptoms and daily life of people with HCM.

Throughout the study, participants will be asked to complete questionnaires about their symptoms and how they feel. They will also undergo tests like echocardiograms, which use sound waves to create images of the heart, to measure changes in the heart’s function. The study will help determine if Sotagliflozin can be a beneficial treatment option for people with Hypertrophic Cardiomyopathy.

The purpose of the study is to compare the effects of Aficamten with a placebo in young participants who have oHCM. Participants will be randomly assigned to receive either Aficamten or a placebo. The study will be conducted in two parts. In the first part, participants will take the medication or placebo for a period of 12 weeks. During this time, doctors will monitor changes in the heart’s function and any side effects. After completing the first part, participants may continue into an open-label extension, where everyone will receive Aficamten, to further assess its long-term safety and effectiveness.

Throughout the study, participants will have regular check-ups to monitor their heart health and overall well-being. The study aims to provide valuable information on how Aficamten can help manage symptoms of oHCM in a pediatric population, potentially leading to improved treatment options for this condition.

The purpose of this study is to determine if Mavacamten can effectively reduce the thickness of the heart wall and the size of the atria in patients with oHCM. Participants in the study will be randomly assigned to receive either Mavacamten or a placebo, which is a capsule that looks like the medication but does not contain the active ingredient. The study will last for a period of 96 weeks, during which participants will have regular check-ups and imaging tests to monitor their heart condition.

Throughout the study, the impact of Mavacamten on heart function will be assessed, including any improvements in symptoms related to heart failure. The study will also monitor for any other heart-related events to ensure the safety of the treatment. The goal is to see if Mavacamten can provide a beneficial effect on the heart’s structure and function in people with oHCM.

The purpose of the study is to assess how Aficamten affects the health status and exercise capacity of participants with this heart condition. Participants will be randomly assigned to receive either Aficamten or a placebo. The study will be conducted in a double-blind manner, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure the results are unbiased. The trial will last for a period of 72 weeks, during which participants will undergo regular assessments to monitor their health and response to the treatment.

Throughout the study, participants will have their exercise capacity measured, which involves evaluating how well they can perform physical activities. The study will also monitor changes in their heart condition and overall health. The goal is to determine if Aficamten can improve symptoms and quality of life for those living with symptomatic non-obstructive hypertrophic cardiomyopathy. This research could potentially lead to new treatment options for individuals affected by this heart condition.

Participants in the study will receive multiple doses of MYK-224 over a period of time. The study will monitor how the body processes the medication and its effects on the heart condition. Participants will be observed for any side effects and changes in their heart function. The study is designed to gather information on how effective the medication is in treating the symptoms of Hypertrophic Cardiomyopathy and improving the heart’s ability to pump blood.

The study is divided into two parts. In the first part, participants will receive the medication and be closely monitored. Those who complete the first part may have the option to continue into the second part, which is an extended study lasting up to two years. Throughout the study, participants will undergo regular check-ups, including heart function tests, to ensure their safety and to collect data on the medication’s effects.

Participants in the study will be randomly assigned to receive either Mavacamten or a placebo, which looks like the medication but does not contain the active ingredient. The study will last for several months, during which participants will take the capsules and have regular check-ups to monitor their heart health. The main focus will be on changes in the heart’s function, particularly in the area called the left ventricular outflow tract, which is often affected in this condition.

Throughout the study, doctors will assess various aspects of heart health, including how well the heart pumps blood and any changes in heart muscle thickness. The study will also look at how participants feel during physical activities and any side effects they might experience. The goal is to gather information on the effectiveness and safety of Mavacamten for treating Symptomatic Obstructive Hypertrophic Cardiomyopathy in young people.

Participants in the study will take Aficamten in the form of a film-coated tablet, which is taken orally. The study will monitor patients over a period to observe any side effects or changes in their condition. The study aims to ensure that Aficamten is safe for long-term use and to understand how it affects the heart’s function in people with HCM. The study will also compare the effects of Aficamten with a placebo to determine its effectiveness.

Throughout the study, researchers will keep track of any adverse events, which are any unwanted effects that occur during the trial. They will also monitor the heart’s performance, specifically looking at the heart’s ability to pump blood effectively. This will help determine if Aficamten can be a safe and effective treatment option for people living with symptomatic HCM. The study is designed to provide valuable insights into the management of this heart condition and improve treatment options for patients in the future.

Participants in the study will receive either Bisoprolol, Verapamil, or a placebo. Bisoprolol is a medication that helps lower blood pressure and reduce heart rate, while Verapamil is used to relax the heart muscles and improve blood flow. The study will last for a period of three months, during which the effects of these medications on heart function and symptoms will be monitored. The study aims to measure changes in the heart’s ability to pump blood, the size of the heart chambers, and the occurrence of irregular heartbeats.

Throughout the study, participants will undergo various tests to assess their heart health, including measurements of oxygen consumption and heart volume. The study will also look at how these medications affect the quality of life and symptom severity in patients. By the end of the study, researchers hope to better understand how Bisoprolol and Verapamil can be used to manage symptoms in people with non-obstructive hypertrophic cardiomyopathy.

The purpose of this study is to assess how well participants tolerate Mavacamten over a longer period. Participants will take Mavacamten in capsule form, with doses ranging from 2.5 mg to 15 mg. The study will monitor the participants for any major heart-related events, such as heart attacks or strokes, as well as hospitalizations and other heart conditions like heart failure or irregular heartbeats. The study will also look at changes in the heart’s structure and function using imaging techniques like cardiac magnetic resonance imaging (MRI).

Throughout the study, participants will be regularly checked for any side effects or changes in their heart condition. The study aims to provide valuable information on the long-term use of Mavacamten for managing Hypertrophic Cardiomyopathy, helping to understand its safety and effects on heart health over time.

The purpose of the study is to evaluate how well Aficamten improves exercise capacity in people with oHCM compared to Metoprolol. Participants will be randomly assigned to receive either Aficamten, Metoprolol, or a placebo. The study will last for about 24 weeks, during which participants will take their assigned medication and undergo various assessments to monitor their heart function and overall health. These assessments will include tests to measure how much oxygen the body uses during exercise, as well as questionnaires to evaluate symptoms and quality of life.

Throughout the study, participants will have regular check-ups to ensure their safety and to track any changes in their condition. The trial is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving which treatment until the study is completed. This helps to ensure that the results are unbiased and reliable. The ultimate goal is to determine whether Aficamten can offer a new and effective treatment option for people living with oHCM.

The purpose of this research is to determine if taking empagliflozin tablets (10 mg daily) for twelve months can improve the ability to exercise in people with Hypertrophic Cardiomyopathy. During the study, participants will be divided into two groups – one group will receive empagliflozin while the other will receive a placebo.

The medication being tested, empagliflozin, is already approved for other medical conditions. The study will last for twelve months, during which participants will need to take one tablet daily. Throughout the study, doctors will monitor how well participants can exercise and how their heart condition responds to the treatment.